Emyria Limited, a clinical-stage biotech company, engages in the development of treatments for unmet medical needs. The company develops psychedelic-assisted therapy, as well as MDMA drug discovery program. Its drug development program includes EMD-RX5 for treatment of psychological distress and mild stress and anxiety. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was founded in 2018 and is headquartered in Leederville, Australia.
| Market Capitalization | $24.6679 million |
| P/E Ratio | 0 |
| P/E Growth Ratio | |
| Book Value | 0.018 |
| Dividend Per Share | 0 |
| Earnings Per Share | -0.03 |
| EBITDA | -6,894.726 |
| Profit Margin | 0 |
| Operating Margin TTM | -3.9594 |
| Return on Assets TTM | -0.4494 |
| Return on Equity TTM | -1.0028 |
| Revenue TTM | 1,772.098 |
All numbers are in thousands
| Date | Total Revenue | Cost of Revenue | Gross Profit | Total Operating Expenses |
|---|---|---|---|---|
| 2018-06-30 | 0 | 257.3 | ||
| 2019-06-30 | 109.91 | 646.3 | -536.39 | 2,610.157 |
| 2020-06-30 | 1,013.452 | 1,938.477 | -925.025 | 4,706.116 |
| 2021-06-30 | 1,207.543 | 2,264.272 | -1,056.729 | 5,422.474 |
| 2022-06-30 | 1,352.592 | 2,347.654 | -995.062 | 8,013.081 |
| 2023-06-30 | 1,592.466 | 2,239.975 | -647.509 | 6,475.114 |
All numbers are in thousands
| Date | Cash | Total Assets | Total Liabilities | Short Term Debt | Long Term Debt | Common Stock |
|---|---|---|---|---|---|---|
| 2018-06-30 | 3,039.492 | 3,058.83 | 250.43 | 0 | 2,872.738 | |
| 2019-06-30 | 8,885.592 | 9,751.686 | 272.748 | 0 | 2,752.62 | 13,004.088 |
| 2020-06-30 | 3,686.333 | 5,064.944 | 1,282.027 | 399.843 | 0 | 11,751.953 |
| 2021-06-30 | 6,528.926 | 9,059.559 | 1,881.342 | 197.63 | 19,310.804 | |
| 2022-06-30 | 3,879.469 | 8,247.835 | 1,925.978 | 268.887 | 24,637.314 | |
| 2023-06-30 | 2,733.526 | 10,163.958 | 3,370.343 | 1,131.005 | 29,803.915 |
All numbers are in thousands
| Date | Net Income | Total Cash | Change in Cash | Begin period cash | End period cash | Dividends |
|---|---|---|---|---|---|---|
| 2018-06-30 | -257.36 | -20.82 | 3,039.49 | |||
| 2019-06-30 | -2,682.928 | -2,593.222 | -430.678 | 2,608.814 | ||
| 2020-06-30 | -5,238.04 | -4,452.471 | 1,077.519 | 2,608.814 | 3,686.333 | |
| 2021-06-30 | -4,906.234 | -3,937.319 | 2,842.593 | 3,686.333 | 6,528.926 | |
| 2022-06-30 | -7,399.915 | -7,009.912 | -2,649.457 | 6,528.926 | 3,879.469 | |
| 2023-06-30 | -5,131.117 | -3,754.77 | -1,145.943 | 3,879.469 | 2,733.526 |